168 related articles for article (PubMed ID: 23558569)
21. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
22. PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma.
Chapel DB; Husain AN; Krausz T; McGregor SM
Am J Surg Pathol; 2017 Dec; 41(12):1675-1682. PubMed ID: 28877056
[TBL] [Abstract][Full Text] [Related]
23. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
Vang R; Shih IeM; Kurman RJ
Adv Anat Pathol; 2009 Sep; 16(5):267-82. PubMed ID: 19700937
[TBL] [Abstract][Full Text] [Related]
24. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
25. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
26. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
Kang EY; Cheasley D; LePage C; Wakefield MJ; da Cunha Torres M; Rowley S; Salazar C; Xing Z; Allan P; Bowtell DDL; Mes-Masson AM; Provencher DM; Rahimi K; Kelemen LE; Fasching PA; Doherty JA; Goodman MT; Goode EL; Deen S; Pharoah PDP; Brenton JD; Sieh W; Mateoiu C; Sundfeldt K; Cook LS; Le ND; Anglesio MS; Gilks CB; Huntsman DG; Kennedy CJ; Traficante N; ; DeFazio A; Kaufmann S; Churchman M; Gourley C; Stephens AN; Meagher NS; Ramus SJ; Antill YC; Campbell I; Scott CL; Köbel M; Gorringe KL;
Mod Pathol; 2021 Jan; 34(1):194-206. PubMed ID: 32724153
[TBL] [Abstract][Full Text] [Related]
27. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
[TBL] [Abstract][Full Text] [Related]
28. B7-H4 expression in ovarian serous carcinoma: a study of 306 cases.
Liang L; Jiang Y; Chen JS; Niu N; Piao J; Ning J; Zu Y; Zhang J; Liu J
Hum Pathol; 2016 Nov; 57():1-6. PubMed ID: 27349304
[TBL] [Abstract][Full Text] [Related]
29. SOX6 Expression Is Sensitive for Peritoneal Epithelioid Malignant Mesothelioma, But Not Specific in the Differential Diagnosis With Tubo-ovarian Serous Neoplasia.
Chapel DB; Hirsch MS
Am J Surg Pathol; 2022 Feb; 46(2):213-219. PubMed ID: 34411029
[TBL] [Abstract][Full Text] [Related]
30. Expression of Nestin and CD133 in serous ovarian carcinoma.
Onisim A; Iancu M; Vlad C; Kubelac P; Fetica B; Fulop A; Achimas-Cadariu A; Achimas-Cadariu P
J BUON; 2016; 21(5):1168-1175. PubMed ID: 27837619
[TBL] [Abstract][Full Text] [Related]
31. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of microinvasion and lymph node involvement in ovarian serous borderline/atypical proliferative serous tumors: a morphologic and immunohistochemical analysis of 37 cases.
Maniar KP; Wang Y; Visvanathan K; Shih IeM; Kurman RJ
Am J Surg Pathol; 2014 Jun; 38(6):743-55. PubMed ID: 24441661
[TBL] [Abstract][Full Text] [Related]
33. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.
Morrison JC; Blanco LZ; Vang R; Ronnett BM
Am J Surg Pathol; 2015 Apr; 39(4):442-53. PubMed ID: 25517955
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
35. Expression of p16, p53, CD24, EpCAM and calretinin in serous borderline tumors of the ovary.
Aktaş IY; Buğdayci M; Usubütün A
Turk Patoloji Derg; 2012; 28(3):220-30. PubMed ID: 23011824
[TBL] [Abstract][Full Text] [Related]
36. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA signatures discriminate between uterine and ovarian serous carcinomas.
Hui P; Gysler SM; Uduman M; Togun TA; Prado DE; Brambs CE; Nallur S; Schwartz PE; Rutherford TJ; Santin AD; Weidhaas JB; Ratner ES
Hum Pathol; 2018 Jun; 76():133-140. PubMed ID: 29518404
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression.
Nilforoushan N; Moatamed NA
Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902
[TBL] [Abstract][Full Text] [Related]
39. Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma.
Phillips V; Kelly P; McCluggage WG
Int J Gynecol Pathol; 2009 Mar; 28(2):179-86. PubMed ID: 19188815
[TBL] [Abstract][Full Text] [Related]
40. CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
Davidson B
Hum Pathol; 2016 Dec; 58():123-127. PubMed ID: 27589896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
